Perrigo Company reported a 3.2% decline in second-quarter net sales to $1.02 billion, impacted by category softness and macroeconomic challenges, but achieved market share growth in U.S. store-brand OTC and key European brands. The company completed the sale of its Dermacosmetics business and is reviewing its Infant Formula and Oral Care segments as part of its strategic portfolio streamlining. Despite short-term pressures, Perrigo reaffirmed its full-year 2026 outlook, expecting stronger second-half performance supported by operational improvements and market share gains. The company continues to focus on debt reduction, operational efficiency, and long-term shareholder value creation amid an uncertain economic environment.
Accenture's stock fell 4.73% to $181.29 after Guggenheim reiterated a Neutral rating, citing that the stock price has outpaced the company's actual business performance. Analysts point to weak customer demand, fewer job postings, and a cautious mid-m...
Thryv Holdings is selling its traditional print directory business for $142 million to focus on business automation software for small and medium businesses. CEO Walsh Joe bought 25,000 shares at $1.80 each, increasing his stake to 788,099 shares, si...
Tempus AI's stock surged 29% in one week, driven by positive analyst commentary and new revenue prospects from reimbursement changes. Goldman Sachs initiated coverage with a Neutral rating and a $75 price target, while technical indicators like a tri...
Seagate Technology's stock is predicted to hit $900 per share on October 27, 2026, coinciding with its fiscal Q1 2027 earnings release. The company has guided revenue around $4.10 billion and non-GAAP EPS near $7.30, following four consecutive quarte...
The Schwab U.S. Dividend Equity ETF (SCHD) remains a strong choice for income-focused investors due to its disciplined approach and low costs. Its recent portfolio update increased holdings in recession-resistant sectors like Healthcare (21%) and Con...
